Repligen
RGEN
#2411
Rank
โ‚น749.40 B
Marketcap
โ‚น13,286
Share price
-1.78%
Change (1 day)
31.23%
Change (1 year)
Categories

P/E ratio for Repligen (RGEN)

P/E ratio as of July 2026 (TTM): 150

According to Repligen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 149.565. At the end of 2025 the company had a P/E ratio of 188.

P/E ratio history for Repligen from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025188-166.73%
2024-282-217.73%
2023240375.76%
202250.4-55.48%
2021113-32.67%
2020168-18.22%
201920648.11%
2018139179.26%
201749.7-43.56%
201688.1-9.73%
201597.623.17%
201479.2184.52%
201327.8103.9%
201213.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Pfizer
PFE
19.1-87.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
31.4-79.00%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
40.8-72.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
17.3-88.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
-0.1947-100.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
-14.5-109.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
26.0-82.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
101-32.41%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
42.1-71.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
-61.1-140.88%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.